Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: DNA

Ginkgo Bioworks Holdings, Inc.

Healthcare | Biotechnology

No licensed closing price on file for DNA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-5.00

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 10:54 UTC.

What Ginkgo Bioworks Holdings, Inc. does

Ginkgo Bioworks Holdings, Inc. operates two business segments that serve government and commercial customers. In cell engineering, the company provides research and development services and tools to help customers discover and manufacture new biological products across medicine, agriculture, industrial biotechnology, and government sectors. The company also offers data generation, artificial intelligence tools, and licenses to biological assets that improve with scale across successive projects.

Summarized from Ginkgo Bioworks Holdings, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-5.00

Revenue, margins & earnings

FY2021: net loss $1.83B on revenue $314M$314MFY2021FY2022: net loss $2.10B on revenue $478M$478MFY2022FY2023: net loss $893M on revenue $251M$251MFY2023FY2024: net loss $547M on revenue $227M$227MFY2024FY2025: net loss $313M on revenue $170M$170MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-07
  • 2026-10-07See remarksSale-2,403$36.0K
  • 2026-09-16DirectorSale-5,000$35.4K
  • 2026-08-25See remarksRestricted Stock UnitsOption exercise-587—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Ginkgo Bioworks Holdings, Inc. do?

Ginkgo Bioworks Holdings, Inc. is a biotechnology company, listed on NYSE as DNA.

When did DNA last file with the SEC?

Ginkgo Bioworks Holdings, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 10:54 UTC. This page is also available as JSON at /api/data?ticker=DNA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DNA and 5,000+ tickers.

Create a free account — keep DNA
For your agent
GET /api/data?ticker=DNA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt